Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126099 · ClinicalTrials.gov registry record · NA
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
A NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01126099: Completed NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT01126099 is a NA study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01126099, a NA study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be effective in treating behavioral problems by reducing excess adrenalin effects in the brain.
Primary Outcome
This scale represents the raters overall impression of improvement or worsening, and is assessed at the last visit. 1 = Marked improvement, 1 = Moderate improvement, 3 = Minimal improvement, 4 = No change, 5 = Minimal worsening, 6 = Moderate worsening, 7 = Marked worsening.
Interventions
- DRUG Placebo
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT01126099 record still lists
NCT01126099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01126099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01126099 about?
NCT01126099 is a clinical study titled "Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease". A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be eff...
What is the current status of trial NCT01126099?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2010-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01126099?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT01126099?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01126099's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia